SUMO3: A Potential Drug Target and Biomarker for Small Ubiquitin-Related Modifier 3

Target Name: SUMO3

NCBI ID: G6612

SUMO3

SUMO3: A Potential Drug Target and Biomarker for Small Ubiquitin-Related Modifier 3

Small ubiquitin-related modifier 3 (SUMO3) is a protein that plays a crucial role in the ubiquitin system, a protein-protein interaction network that is involved in various cellular processes, including cell signaling, DNA replication, and stress response. SUMO3 is a key regulator of the ubiquitin system, and its dysfunction has been implicated in numerous diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. As a result, SUMO3 has become an attractive drug target and a potential biomarker for various diseases.

Diseases associated with SUMO3 dysfunction

SUMO3 plays a critical role in the regulation of DNA replication, cell signaling, and stress response, and its dysfunction has been implicated in numerous diseases. One of the most well-known diseases associated with SUMO3 dysfunction is cancer. SUMO3 has been shown to play a role in the regulation of DNA replication in various cell types, and its dysfunction has been implicated in the development of various cancers, including breast, ovarian, and prostate cancers.

SUMO3 has also been shown to play a role in the regulation of cell signaling, including the Wnt signaling pathway. Wnt signaling is a critical signaling pathway that is involved in the development and maintenance of tissues, and SUMO3 has been shown to regulate the activity of Wnt signaling pathway proteins, including Wnt-1, Wnt-2, and Wnt-3.

In addition to its role in cell signaling, SUMO3 has also been shown to play a role in the regulation of stress response. SUMO3 has been shown to regulate the activity of various stress-responsive pathways, including the GADD45-CREB signaling pathway, which is involved in the regulation of stress response and cell survival.

Potential drug targets and biomarkers

SUMO3 has been shown to be a potential drug target for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. One of the most promising drug targets for SUMO3 is the inhibition of SUMO3 activity, which has been shown to have therapeutic effects in a variety of diseases.

One of the most promising strategies for inhibiting SUMO3 activity is the use of small molecule inhibitors. Small molecule inhibitors have been shown to be effective in inhibiting the activity of various SUMO3-interactive proteins, including SUMO3 itself. In addition, small molecule inhibitors have also been shown to be effective in treating a variety of diseases associated with SUMO3 dysfunction, including cancer, neurodegenerative diseases, and autoimmune disorders.

Another potential biomarker for SUMO3 dysfunction is the measurement of SUMO3 levels in various tissues and fluids. SUMO3 levels have been shown to be elevated in various tissues and fluids associated with diseases associated with SUMO3 dysfunction, including cancer, neurodegenerative diseases, and autoimmune disorders. The measurement of SUMO3 levels may be a useful diagnostic tool for evaluating the severity of SUMO3 dysfunction in these diseases.

Conclusion

SUMO3 is a protein that plays a crucial role in the regulation of the ubiquitin system and its dysfunction has been implicated in a variety of diseases. As a result, SUMO3 has become an attractive drug target and a potential biomarker for various diseases. The inhibition of SUMO3 activity using small molecule inhibitors has shown to have therapeutic effects in a variety of diseases associated with SUMO3 dysfunction, including cancer, neurodegenerative diseases, and autoimmune disorders. Further research is needed to fully understand the role of SUMO3 in the regulation of the ubiquitin system and its potential as a drug target and biomarker

Protein Name: Small Ubiquitin Like Modifier 3

Functions: Ubiquitin-like protein which can be covalently attached to target lysines either as a monomer or as a lysine-linked polymer. Does not seem to be involved in protein degradation and may function as an antagonist of ubiquitin in the degradation process. Plays a role in a number of cellular processes such as nuclear transport, DNA replication and repair, mitosis and signal transduction. Covalent attachment to its substrates requires prior activation by the E1 complex SAE1-SAE2 and linkage to the E2 enzyme UBE2I, and can be promoted by an E3 ligase such as PIAS1-4, RANBP2 or CBX4 (PubMed:11451954, PubMed:18538659, PubMed:21965678). Plays a role in the regulation of sumoylation status of SETX (PubMed:24105744)

The "SUMO3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SUMO3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets